Abstract 902P
Background
Cisplatin (CDDP) is the most frequently used chemotherapeutic agent for head and neck cancer (HNC). The objectives of this study were to estimate the incidence rate of CDDP-induced ototoxicity (CIO) and the threshold dose causing ototoxicity, and reveal the related factors in HNC.
Methods
Three hundred and thirty-two patients of HNC received chemotherapy containing CDDP at Kyoto University Hospital from June 2009 to December 2022. The distortion product otoacoustic emission (DPOAE), tympanometry (TPG), and pure-tone audiometry (PTA) were measured after each administration of CDDP. Patients with bilateral conductive hearing loss, and/or the ear side with otitis media were excluded. The factors associated with CIO synergistically were investigated by evaluating the baseline characteristics.
Results
A total of 304 of the 332 patients were included in the analysis. The mean age before CDDP administration was 60.5 years (range, 24-79). Primary sites were nasopharynx (6.6%), oropharynx (21.1%), hypopharynx (20.7%), larynx (7.2%), oral cavity (28.3%), paranasal sinuses (8.9%), and other sites (7.2%). The mean cumulative CDDP doses were 200.0 mg/m2 (range, 48- 800, median 190.0). Dose-dependent hearing threshold shift was observed mainly in the high-frequency speech range. The incidence rate of ototoxicity detected by DPOAE and PTA were 46.4% and 37.8%, respectively. The median cisplatin doses causing deterioration of DPOAE were lower than PTA (210.0 mg/m2 v.s.258.0 mg/m2, p < 0.05). Above 300 mg/m2 of cumulative CDDP dose, CIO was detected in 56.5% by PTA. Related factors for CIO were the cumulative doses of CDDP, concurrent use of radiotherapy, and high-frequency hearing impairment before treatment (p < 0.05, respectively).
Conclusions
Implicit hearing loss caused by CDDP was observed at dose of 211 mg/m2, although subjective hearing loss appeared at dose of 258 mg/m2. Cumulative doses of CDDP, concurrent use of radiotherapy, and high-frequency hearing impairment before treatment were identified as risk factors for CIO. Monitoring of hearing level is suggested for early detection of CIO especially in patients with high-frequency hearing impairment before treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
878P - INHBA is overexpressed in HPV-negative oropharyngeal squamous cell carcinoma and contributes to an aggressive phenotype
Presenter: Simon Laban
Session: Poster session 12
880P - ctHPV16-DNA in Liquid Biopsy: A promising biomarker to monitor disease status in patients with HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Nora Würdemann
Session: Poster session 12
881P - SOTO study: Prospective study to correlate the treatment sensitivity of patient-derived organoids (PDOs) with treatment outcomes in head and neck cancer patients
Presenter: Ifigenia Vasiliadou
Session: Poster session 12
882P - Claudin-1 (CLDN1) expression in head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Stefano Cavalieri
Session: Poster session 12
884P - Prognostic value and immune characteristics of LGALS1 in head and neck squamous cell carcinoma
Presenter: Yanfei Min
Session: Poster session 12
885P - Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in nasopharyngeal carcinoma
Presenter: Dingyi Wang
Session: Poster session 12
887P - Antitumor activity of the radioenhancer NBTXR3 on injected lesions to estimate overall survival: Exploratory analyses from a phase I in cisplatin-ineligible locally advanced HNSCC patients
Presenter: Christophe Le Tourneau
Session: Poster session 12
888P - Phase I study of olaparib combined with loco-regional radiotherapy in patients with head and neck squamous cell carcinoma
Presenter: Marcel Verheij
Session: Poster session 12